Evidence map›Paper›PMID 37162451›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2023

ISCOMs/MPLA-Adjuvanted SDAD Protein Nanoparticles Induce Improved Mucosal Immune Responses and Cross-Protection in Mice.

Wandi Zhu, Jaeyoung Park, Thomas Pho, Lai Wei, Chunhong Dong, Joo Kim, Yao Ma, Julie A Champion, Bao-Zhong Wang

Open access · greenAbstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Inverted HA-EV immunization elicits stalk-specific influenza immunity and cross-protection in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Wandi ZhuCenter for Inflammation, Immunity and Infection, Georgia State University, Atlanta, GA, 30303, USA.
Jaeyoung ParkSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Thomas PhoSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Lai WeiCenter for Inflammation, Immunity and Infection, Georgia State University, Atlanta, GA, 30303, USA.
Chunhong DongCenter for Inflammation, Immunity and Infection, Georgia State University, Atlanta, GA, 30303, USA.
Joo KimCenter for Inflammation, Immunity and Infection, Georgia State University, Atlanta, GA, 30303, USA.
Yao MaCenter for Inflammation, Immunity and Infection, Georgia State University, Atlanta, GA, 30303, USA.
Julie A ChampionSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Bao-Zhong WangCenter for Inflammation, Immunity and Infection, Georgia State University, Atlanta, GA, 30303, USA.ORCID 0000-0002-1561-4318
Georgia State University · USGeorgia Institute of Technology · US

Funding

Novel Influenza nano vaccines for broad cross protectionR01AI101047 · NIAID · GEORGIA STATE UNIVERSITY · PI WANG, BAOZHONG · 2012 to 2023
$6.1M
Multivalent nanocluster universal influenza vaccine given by microneedle patchR01AI143844 · NIAID · GEORGIA STATE UNIVERSITY · PI WANG, BAOZHONG · 2019 to 2023
$3.9M
NIAID NIH HHS R01 AI101047NIAID NIH HHS R01 AI143844
6 · The paper itself

Abstract

The epidemics caused by the influenza virus are a serious threat to public health and the economy. Adding appropriate adjuvants to improve immunogenicity and finding effective mucosal vaccines to combat respiratory infection at the portal of virus entry are important strategies to boost protection. In this study, a novel type of core/shell protein nanoparticle consisting of influenza nucleoprotein (NP) as the core and NA1-M2e or NA2-M2e fusion proteins as the coating antigens by SDAD hetero-bifunctional crosslinking is exploited. Immune-stimulating complexes (ISCOMs)/monophosphoryl lipid A (MPLA) adjuvants further boost the NP/NA-M2e SDAD protein nanoparticle-induced immune responses when administered intramuscularly. The ISCOMs/MPLA-adjuvanted protein nanoparticles are delivered through the intranasal route to validate the application as mucosal vaccines. ISCOMs/MPLA-adjuvanted nanoparticles induce significantly strengthened antigen-specific antibody responses, cytokine-secreting splenocytes in the systemic compartment, and higher levels of antigen-specific IgA and IgG in the local mucosa. Meanwhile, significantly expanded lung resident memory (RM) T and B cells (T

Indexed as

Influenza VaccinesISCOMsNanoparticlesAdjuvants, ImmunologicAnimalsAntigen-Antibody ComplexImmunity, MucosalInfluenza A Virus, H3N2 SubtypeLipid AMiceMice, Inbred BALB CAdjuvants, ImmunologicAntigen-Antibody ComplexInfluenza VaccinesISCOMsLipid Amonophosphoryl lipid Aadjuvantinfluenza virusintranasal deliverymucosal vaccinesprotein nanoparticles

Identifiers

PMID37162451
PMCPMC10524461
OpenAlexW4376121578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.